Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) EBIT (2017 - 2022)

Historic EBIT for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to -$7.9 million.

  • Iterum Therapeutics' EBIT fell 1606.38% to -$7.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$30.4 million, marking a year-over-year decrease of 2382.52%. This contributed to the annual value of -$18.7 million for FY2024, which is 6061.35% up from last year.
  • As of Q4 2022, Iterum Therapeutics' EBIT stood at -$7.9 million, which was down 1606.38% from -$7.0 million recorded in Q3 2022.
  • Over the past 5 years, Iterum Therapeutics' EBIT peaked at -$4.6 million during Q4 2020, and registered a low of -$31.0 million during Q3 2019.
  • Moreover, its 5-year median value for EBIT was -$8.2 million (2020), whereas its average is -$13.3 million.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 20118.13% in 2018, then skyrocketed by 7996.38% in 2020.
  • Iterum Therapeutics' EBIT (Quarter) stood at -$23.9 million in 2018, then increased by 3.2% to -$23.2 million in 2019, then skyrocketed by 79.96% to -$4.6 million in 2020, then crashed by 47.05% to -$6.8 million in 2021, then decreased by 16.06% to -$7.9 million in 2022.
  • Its last three reported values are -$7.9 million in Q4 2022, -$7.0 million for Q3 2022, and -$8.0 million during Q2 2022.